A recent study showed no significant difference in COVID-19 disease severity, progression, mortality or hospitalization between high-risk patients who received convalescent plasma and those who received placebo. Another top story explored the biological differences between early-onset and average-onset colorectal cancer. Researchers reported that they were “genomically indistinguishable,” suggesting that more aggressive treatment for early-onset colorectal cancer is neither necessary nor effective.

Early convalescent plasma fails to prevent COVID-19 progression in high-risk outpatients

COVID-19 convalescent plasma administered within 7 days of symptom onset did not appear to prevent disease progression among high-risk outpatients with COVID-19,

arly-onset colorectal cancer may not be biologically different from average-onset disease

Early-onset colorectal cancer did not appear genomically distinct from average-onset disease, according to results of a retrospective, single-institution analysis

Long-term effects of COVID-19 and cancer create population of ‘dual survivors’

The late effects of cancer and its treatment are well documented and may extend years beyond active treatment.

Post-transplant cyclophosphamide increases risk for early cardiac events

Post-transplant cyclophosphamide reduced incidence of graft-versus-host disease but led to higher incidence of early cardiac events after allogeneic hematopoietic stem cell transplantation,

Submit manuscript at https://www.longdom.org/submissions/blood-disorders-transfusion.html 

Regards
Sarah eve

Managing Editor

Journal of Blood Disorders and Transfusion